Abstract
A constantly growing body of research has been performed mainly over the past decade and a half, aiming to facilitate our still limited understanding of the biology and function of various different cell types which collectively have been termed endothelial progenitor cells. This review intends to critically outline aspects of terminology, origin and applicability of the somatic progenitors which are thought to maintain integrity and support regeneration of the inner lining of vessels through proliferation. Despite reasonable progress in the field, we are still not confident regarding the precise phenotype and function of endothelial progenitor cells. Model systems that have been developed to study the vascular regenerative potential of human endothelial progenitor cells in animal models in vivo present principle tools for testing new agents that modulate vascular homeostasis and regeneration.
Keywords: EPC, ECFC, EC, endothelial cells, stem cells, progenitor cells, transplantation, vascular homeostasis, myeloid cells, mesenchymal stromal/stem cells
Current Pharmaceutical Design
Title: Endothelial Progenitor Cells: Quod Erat Demonstrandum?
Volume: 17 Issue: 30
Author(s): Dirk Strunk
Affiliation:
Keywords: EPC, ECFC, EC, endothelial cells, stem cells, progenitor cells, transplantation, vascular homeostasis, myeloid cells, mesenchymal stromal/stem cells
Abstract: A constantly growing body of research has been performed mainly over the past decade and a half, aiming to facilitate our still limited understanding of the biology and function of various different cell types which collectively have been termed endothelial progenitor cells. This review intends to critically outline aspects of terminology, origin and applicability of the somatic progenitors which are thought to maintain integrity and support regeneration of the inner lining of vessels through proliferation. Despite reasonable progress in the field, we are still not confident regarding the precise phenotype and function of endothelial progenitor cells. Model systems that have been developed to study the vascular regenerative potential of human endothelial progenitor cells in animal models in vivo present principle tools for testing new agents that modulate vascular homeostasis and regeneration.
Export Options
About this article
Cite this article as:
Strunk Dirk, Endothelial Progenitor Cells: Quod Erat Demonstrandum?, Current Pharmaceutical Design 2011; 17 (30) . https://dx.doi.org/10.2174/138161211797904127
DOI https://dx.doi.org/10.2174/138161211797904127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Current Cancer Drug Targets Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: New Generation Cancer Vaccines: From Tumor Immunology to Clinical Applications (Executive Editor: Simone Mocellin)]
Current Pharmaceutical Design Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Translational Multimodality Neuroimaging
Current Drug Targets NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Natural Compounds in Anti-Leukaemic Therapy: A Review
Mini-Reviews in Medicinal Chemistry